On January 4, 2022 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, reported that it will participate in the virtual 40th Annual J.P. Morgan Healthcare Conference (Press release, Novavax, JAN 4, 2022, View Source [SID1234598138]). Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Presentation and Q&A

Date:

Monday, January 10, 2022

Time:

9:00 – 9:40 a.m. Eastern Time (ET)

Moderator:

Eric Joseph

Novavax participants:

Stanley C. Erck, President and Chief Executive Officer

Conference

Event:

Investor meetings

Date:

Monday, January 10, 2022 – Wednesday, January 12, 2022

An audio replay of the recorded presentation and Q&A will be available through the events page of the Company’s website at ir.novavax.com for 30 days.